Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07658196 · ClinicalTrials.gov registry record · Phase 1
TLR9 Immunotherapy for Peritoneal Carcinomatosis
A Phase 1 study, sponsored by Brown University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07658196 is a Phase 1 study that has not yet begun recruiting, run by Brown University. The registered enrollment target is 24 participants.
The verdict
NCT07658196, a Phase 1 study, has not yet begun recruiting, sponsored by Brown University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are: • To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal injection(s) of ACM-CpG for inoperable peritoneal metastases or malignant ascites? Researchers will assign treatment levels using escalating doses of ACM-CpG Therapy. Participants will: * Will receive at least one dose of ACM-CpG therapy on Day 1 of a 28-day treatment cycle. * May receive up to 2 additional injections if they have clinically stable or responsive disease. * Must visit the clinic on Days 1, 4, 7, 10, 14, 21, and 28 for checkups and tests. * Will have a CT scan or MRI performed every 8 weeks for 3 scans and then continue to receive scans every 12 weeks to monitor their disease.
Interventions
- DRUG ACM-CpG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07658196
The ClinicalTrials.gov registry entry for NCT07658196 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACM-CpG is the first listed.
NCT07658196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07658196 about?
NCT07658196 is a clinical study titled "TLR9 Immunotherapy for Peritoneal Carcinomatosis". The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are: • To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal inj...
What is the current status of trial NCT07658196?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-07. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07658196?
The interventions under investigation include: ACM-CpG (DRUG).
Who is sponsoring clinical trial NCT07658196?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.